Challenges and opportunities for positron-emission tomography in personalized medicine

IDrugs

Volumn 8, Issue 10, 2005, Pages 827-833

  Smith, Suzanne V ^a  

^a AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

Author keywords

Functional imaging; Personalized medicine; PET probe; Positron emission tomography (PET); Radioisotope; Radiotracer

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 2 NITROIMIDAZOLE; 3' FLUOROTHYMIDINE; ACETIC ACID C 11; BROMINE; CARBON 11; CHOLINE; CHOLINE DERIVATIVE; COPPER 64; DAUNORUBICIN; ESTRADIOL; FLUORIDE SODIUM; FLUORODEOXYGLUCOSE F 18; GALLIUM; GALLIUM 67; IODINE 124; METHIONINE C 11; METIROSINE; MOLYBDENUM 99; NITROGEN 13; OXYGEN 15; RADIOISOTOPE; RADIOLIGAND; RUBIDIUM 82; STRONTIUM 82; TECHNETIUM; TRACER; TYROSINE; UNINDEXED DRUG; YTTRIUM;

ARTICLE; BIOTECHNOLOGY; BONE METASTASIS; BRAIN CIRCULATION; CAMERA; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG HALF LIFE; ECHOGRAPHY; HUMAN; HYPOXIA; IMAGE QUALITY; ISOTOPE LABELING; MALIGNANT NEOPLASTIC DISEASE; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; RADIATION PHYSICS; RADIOISOTOPE DISTRIBUTION; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THREE DIMENSIONAL IMAGING;

COPPER RADIOISOTOPES; HUMANS; POSITRON-EMISSION TOMOGRAPHY;

EID: 26944446531     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Phelps ME: Molecular Imaging with position emission tomography. Annu Rev Nucl Part Sci (2002) 52: 303-338.
2. Jain KK: Personalised medicine. Curr Opin Mol Ther (2002) 4(6):548-558.
3. Smith SV: Molecular imaging with copper-64. J. Inorg Biochem (2004) 9B(11):1874-1901.
4. Gibson RE, Bums HD, Harnill TG, Eng WS, Francis BE, Ryan C: Non-invasive redlotracer imaging as a tool for drug development. Curr Pharm Des (2000) 6(10):973-989.
5. Berridge MS. Heald DL, Lee Z: Imaging studies of biodistribution and kinetics in drug development. Drug Dev Res (2003) 59(2):208-226.
6. Eubank WB, Mankoff DA: Evolving rate of positron emission tomography in breast Cancer imaging. Semin Nucl Med (2005) 36(2): 84-99.
7. Solomon B, McArthur G, Cullinane C, Zalcberg J, Hicks R: Applications of positron emission tomography In the development of molecular targeted cancer therapeutics. BioDrugs (2003) 17(5):339-354.
8. Couturier O, Luxen A, Chatal JF, Vuillez JP, Rigo P, Hustinx R: Fluorinated tracers for imaging cancer with positron emission tomography. Eur J Nucl Med Mol Imaging (2004) 31(8):1182-1206.
9. Fichna J, Janecka A: Synthesis af target-specific radiolaboted peptides for diagnostic imaging. Bioconjug Chem (2003) 14(1):3-17.